Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa
Conditions
Keywords
epidermolysis bullosa, topical treatment
Brief summary
This is a Phase 2, double-blind, randomized, vehicle-controlled study designed to evaluate efficacy, safety, and tolerability of topically applied TCP-25 gel in patients with confirmed DEB or JEB. The study will implement intrasubject randomization, ie, a pair of matching index wounds will be randomly assigned to be treated with a local application of either TCP 25 gel or vehicle gel.
Detailed description
The study will include a Screening Period, a Treatment Period (Days 1 to 56, with study visits conducted every 2 weeks, including the baseline \[Day 1\], Day 14, Day 28, Day 42, and Day 56 visits) and a Safety Follow-up conducted via a telephone/video call at approximately 14 days after the last dose of the IMP. Patients will undergo efficacy, safety, tolerability, and PK assessments at scheduled visits. For evaluation of the primary efficacy endpoint, a trained clinician will take the images of the index wounds at all scheduled visits from baseline through Day 56 (Visit 6) using 3D digital photography and software for wound measurement.
Interventions
DRUGTCP-25 gel
Topical gel
Placebo gel
Sponsors
Xinnate AB
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Intra-subject control
Eligibility
Sex/Gender
ALL
Age
4 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female patients with documented diagnosis of DEB or JEB, confirmed by genetic testing and/or by a skin biopsy with immunofluorescence mapping. * Patients ≥4 years old. Note: Initially, patients ≥12 years will be enrolled. Enrollment will be open to 4 to 11 year old pediatric patients (both inclusive), after a DMC reviews and provides a positive opinion regarding the safety and tolerability of the IMP in at least 3 patients 12 to 18 years old who have completed at least 4 weeks of IMP use.
Exclusion criteria
* The patient has any subtype of EB other than DEB or JEB. * The patient is currently being treated or planned to be treated with systemic antibiotics. Note: Use of preventive and/or anti-inflammatory antibiotic treatment, including doxycycline, on an established treatment regimen (stable dose for ≥6 weeks before the Baseline Visit) is permitted. Use of topical antibiotics on the index wounds within 7 days before the Baseline Visit is prohibited. • Use of systemic corticosteroids \>0.2 mg/kg prednisone dose equivalent per day within 30 days or use of topical corticosteroids on index wounds within 7 days before the Screening Visit. Note: Corticosteroids for inhalation, ophthalmic, or intranasal use are permitted. • The patient has a history of or current malignancy over the index wound, eg, basal cell carcinoma or squamous cell carcinoma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Open wound area | 56 days |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency, intensity, and seriousness of Adverse Events in all treated patients until end of treatment | 56 days | — |
| Change in procedural pain using the Wong Baker FACES® Pain Rating Scale (0 min -10 max) | 56 days | Wong Baker FACES pain rating scale uses 6 graphically or cartoon-depicted faces with varying facial expressions that represent no pain (no hurt) (Face 0) to worst pain/hurt that can be imagined (Face 10). |
| Change from baseline in clinical impression of overall treatment area | 56 days | — |
| TCP-25 plasma concentrations | 56 days | — |
| Number of participants with treatment-related local tolerability assessment at the area of IMP application assessed on a 4-point scale | 56 days | — |
| Clinically significant changes from baseline in blood pressure until end of treatment | 56 days | — |
| Number of patients with clinically significant changes from baseline in pulse rate until end of treatment | 56 days | — |
| Number of patients with clinically significant changes from baseline in physical examination findings until end of treatment | 56 days | — |
Countries
France, Greece, Spain, Sweden
Contacts
CONTACTHead of Clinical Development
Outcome results
None listed